Type 2 Diabetes Clinical Trial
— IDEALOfficial title:
IDEAL: Implementing an Effective Diabetes intervEntion Among Low-income Immigrants
Verified date | March 2024 |
Source | NYU Langone Health |
Contact | Lu Hu, PhD |
Phone | 646-501-3438 |
Lu.hu[@]nyulangone.org | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this IDEAL project is to examine the effectiveness and implementation process of the video-based Diabetes Self-Management Education and Support (DSMES) + community health worker (CHW) (hereafter: "IDEAL") intervention compared with a wait-list control group (hereafter: "CONTROL") to improve glycemic control among Chinese immigrants with Type 2 diabetes (T2D) in New York City (NYC). Participants will be randomized with equal allocation to one of the 2 groups. The IDEAL group will receive 1 DSMES brief video/week for 24 weeks delivered via text message. The CHW will assess participants' SDOH barriers to T2D care and link them to available resources in the community. The CONTROL group will continue to receive their usual care and at the end of the study, they will receive DSMES videos.
Status | Not yet recruiting |
Enrollment | 270 |
Est. completion date | March 31, 2028 |
Est. primary completion date | October 31, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: Participants must: 1. self-identify as a Chinese immigrant; 2. be between 18-70 years old, 3. have a diagnosis of T2D in the medical record; 4. have had an appointment with a physician for routine T2D care within the past 12 months; 5. have a most recent HbA1c > or = 8%; 6. be willing to receive brief videos regarding T2D management, and 7. possess a smartphone or, if they do not have one, be willing and able to use a study smartphone. Exclusion Criteria: 1. unable or unwilling to provide informed consent; 2. unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment); 3. unwilling to accept randomization assignment; 4. is pregnant, plans to become pregnant in the next 6 months, or becomes pregnant during the study, or 5. is breastfeeding (e.g., they may have potential dietary restrictions). |
Country | Name | City | State |
---|---|---|---|
United States | NYU Langone Health | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health | Agency for Healthcare Research and Quality (AHRQ) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Hemoglobin A1C (HbA1c) Test Scores | Scores expressed as a percentage of red blood cells that have sugar-coated hemoglobin.
Patients with Type 2 Diabetes receive a HbA1c blood test at their doctors' office every 3-6 months as part of usual care; testing results will be abstracted from the medical record at the participant's health care facility to minimize participant burden. |
Baseline, Month 6 | |
Primary | Change in Hemoglobin A1C (HbA1c) Test Scores | Scores expressed as a percentage of red blood cells that have sugar-coated hemoglobin.
Patients with Type 2 Diabetes receive a HbA1c blood test at their doctors' office every 3-6 months as part of usual care; testing results will be abstracted from the medical record at the participant's health care facility to minimize participant burden. |
Baseline, Month 12 | |
Secondary | Stanford Self-Efficacy for Diabetes Scale Score | 8-item self-assessment of participants' confidence level in performing specific self-management behaviors. Items are ranked on a 10-point Likert scale ranging from 1 (not at all confident) to 10 (totally confident).
The score is the mean of the 8 items (Range: 1-10); higher scores indicate greater self-efficacy. |
Baseline | |
Secondary | Stanford Self-Efficacy for Diabetes Scale Score | 8-item self-assessment of participants' confidence level in performing specific self-management behaviors. Items are ranked on a 10-point Likert scale ranging from 1 (not at all confident) to 10 (totally confident).
The score is the mean of the 8 items (Range: 1-10); higher scores indicate greater self-efficacy. |
Month 6 | |
Secondary | Stanford Self-Efficacy for Diabetes Scale Score | 8-item self-assessment of participants' confidence level in performing specific self-management behaviors. Items are ranked on a 10-point Likert scale ranging from 1 (not at all confident) to 10 (totally confident).
The score is the mean of the 8 items (Range: 1-10); higher scores indicate greater self-efficacy. |
Month 12 | |
Secondary | Summary of Diabetes Self-Care Activities (SDSCA) Score | 11-item self-report questionnaire assessing participants' adherence to diabetes self-management behaviors. Participants select the number of days (0 to 7) in the past week they have performed the behavior.
The result is an average score between 0 and 7; higher scores indicate better diabetes self-management behavior. |
Baseline | |
Secondary | Summary of Diabetes Self-Care Activities (SDSCA) Score | 11-item self-report questionnaire assessing participants' adherence to diabetes self-management behaviors. Participants select the number of days (0 to 7) in the past week they have performed the behavior.
The result is an average score between 0 and 7; higher scores indicate better diabetes self-management behavior. |
Month 6 | |
Secondary | Summary of Diabetes Self-Care Activities (SDSCA) Score | 11-item self-report questionnaire assessing participants' adherence to diabetes self-management behaviors. Participants select the number of days (0 to 7) in the past week they have performed the behavior.
The result is an average score between 0 and 7; higher scores indicate better diabetes self-management behavior. |
Month 12 | |
Secondary | Starting the Conversation (STC) Diet Scale Score | 8-item self-report questionnaire measuring dietary behaviors. Scores range from 0 to 16; higher scores indicate more dietary behaviors that are not consistent with health. | Baseline | |
Secondary | Starting the Conversation (STC) Diet Scale Score | 8-item self-report questionnaire measuring dietary behaviors. Scores range from 0 to 16; higher scores indicate more dietary behaviors that are not consistent with health. | Month 6 | |
Secondary | Starting the Conversation (STC) Diet Scale Score | 8-item self-report questionnaire measuring dietary behaviors. Scores range from 0 to 16; higher scores indicate more dietary behaviors that are not consistent with health. | Month 12 | |
Secondary | National Cancer Institute Dietary Screener Questionnaire Score | 27-item self-assessment of frequency of consumption of selected foods and drinks over the past month.
The scoring procedure converts responses to estimates of individual dietary intake for: Fruits and Vegetables (cup equivalents); Dairy (cup equivalents); Added Sugars (teaspoon equivalents); Whole Grains (ounce equivalents); Fiber (grams); and Calcium (milligrams). Higher scores indicate higher consumption of the food item. |
Baseline | |
Secondary | National Cancer Institute Dietary Screener Questionnaire Score | 27-item self-assessment of frequency of consumption of selected foods and drinks over the past month.
The scoring procedure converts responses to estimates of individual dietary intake for: Fruits and Vegetables (cup equivalents); Dairy (cup equivalents); Added Sugars (teaspoon equivalents); Whole Grains (ounce equivalents); Fiber (grams); and Calcium (milligrams). Higher scores indicate higher consumption of the food item. |
Month 6 | |
Secondary | National Cancer Institute Dietary Screener Questionnaire Score | 27-item self-assessment of frequency of consumption of selected foods and drinks over the past month.
The scoring procedure converts responses to estimates of individual dietary intake for: Fruits and Vegetables (cup equivalents); Dairy (cup equivalents); Added Sugars (teaspoon equivalents); Whole Grains (ounce equivalents); Fiber (grams); and Calcium (milligrams). Higher scores indicate higher consumption of the food item. |
Month 12 | |
Secondary | International Physical Activity Questionnaire (IPAQ) Short-Version Score | Self-assessment providing an estimate of the number of minutes per week participants engage in three categories of physical activity: vigorous activity, moderate activity, and walking activity.
Results are expressed in metabolic equivalent (MET) minutes per week. MET minutes represent the amount of energy expended carrying out physical activity. The formula for calculating MET is as follows: 8(vigorous activity)(minutes) + 4 (moderate activity)(minutes) +3.3 (walking activity) (minutes) = MET. Higher scores indicate higher weekly levels of physical activity. |
Baseline | |
Secondary | International Physical Activity Questionnaire (IPAQ) Short-Version Score | Self-assessment providing an estimate of the number of minutes per week participants engage in three categories of physical activity: vigorous activity, moderate activity, and walking activity.
Results are expressed in metabolic equivalent (MET) minutes per week. MET minutes represent the amount of energy expended carrying out physical activity. The formula for calculating MET is as follows: 8(vigorous activity)(minutes) + 4 (moderate activity)(minutes) +3.3 (walking activity) (minutes) = MET. Higher scores indicate higher weekly levels of physical activity. |
Month 6 | |
Secondary | International Physical Activity Questionnaire (IPAQ) Short-Version Score | Self-assessment providing an estimate of the number of minutes per week participants engage in three categories of physical activity: vigorous activity, moderate activity, and walking activity.
Results are expressed in metabolic equivalent (MET) minutes per week. MET minutes represent the amount of energy expended carrying out physical activity. The formula for calculating MET is as follows: 8(vigorous activity)(minutes) + 4 (moderate activity)(minutes) +3.3 (walking activity) (minutes) = MET. Higher scores indicate higher weekly levels of physical activity. |
Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |